Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 7/20 | 0.40 |
| ▸ | AVPR1B | P47901 | 7/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495591 | 0.90 | OXTR (0.50) | BRD4ACHEKMT2AMEN1OXTR | |
| SCHEMBL2496335 | 0.88 | AVPR1B (0.48) | BRD4ACHEKMT2AMEN1OXTR | |
| SCHEMBL7082059 | 0.88 | OXTR (0.41) | BRD4ACHEKMT2AMEN1OXTR | |
| SCHEMBL2500309 | 0.84 | AVPR1B (0.47) | BRD4ACHEKMT2AMEN1OXTR | |
| SCHEMBL5070494 | 0.84 | AVPR1A (0.51) | BRD4ACHEKMT2AOXTRAVPR1B | |
| SCHEMBL6947175 | 0.84 | POLB (0.42) | ACHEKMT2AMEN1OXTRAVPR1B | |
| SCHEMBL5065998 | 0.84 | ACHE (0.42) | BRD4ACHEKMT2AOXTRAVPR1B | |
| SCHEMBL6172618 | 0.83 | OXTR (0.48) | BRD4ACHEKMT2AMEN1OXTR | |
| SCHEMBL4590188 | 0.82 | OXTR (0.49) | BRD4ACHEKMT2AMEN1OXTR | |
| SCHEMBL4590101 | 0.81 | OXTR (0.45) | BRD4ACHEKMT2AMEN1OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | BRD4 2445/4885ACHE 4208/4885KMT2A 4115/4885 |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR1B, AVPR2, AVPR1A | BRD4 2256/4885ACHE 3533/4885KMT2A 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.